Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cimzia in moderate to severe ulcerative colitis
NCT01090154Phase 2Completed
- Sponsor
- University of Washington
- Start
- Dec 2010
- Primary completion
- Dec 2021
- Modality
- Antibody Fragments, Polymer-based Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of certolizumab pegol in ulcerative colitis (UC), sponsored by University of Washington. Started Dec 2010; status: completed.
02
Drugs
certolizumab pegol
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT01090154.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01090154.